Newsletters

[ACS Nano] To modulate the oxidative microenvironment and remodel the ECM, a smart microneedle capable of regulating reactive oxygen species and delivering matrix metalloproteinase functions was developed.

[Genome Medicine] This human multi-omics study defines diabetic cardiomyopathy by the concurrent dysregulation of cardiac fuel metabolism, mitochondrial quality control, and matrix remodeling, offering novel mechanistic insights and highlighting acyl-CoA synthetase long-chain family member 1 and BNIP3L as potential therapeutic targets for diabetes-associated cardiac dysfunction.

[Cancer Research] Researchers identified LRRC15⁺ cancer-associated fibroblasts (CAFs) as a tumor-specific CAF subset in lung cancer and proposed LRRC15 as a potential therapeutic target.

[Cancer Immunology Research] To identify the cellular states that drive ECM remodeling, define their organization at the tumor margin, and evaluate their association with prognosis, scientists profiled stromal regions at the tumor margin using single-cell RNA sequencing, spatial transcriptomics, and multiplex immunofluorescence.

[Advanced Healthcare Materials] The authors investigated myocardial decellularized ECM (dECM)-based fibrous scaffolds for iPSC-derived cardiomyocyte use. Coaxially electrospun nanofibers comprising a polyurethane core and a blend of polycaprolactone and myocardial dECM as the sheath were optimized.

[Biofabrication] Scientists established a patient-derived fibrotic tumor model that recapitulates key pathophysiological features: extracellular matrix remodeling, substantial tissue stiffening , and pro-malignant transcriptomic reprogramming.

[European Heart Journal] The authors examine the evolving understanding of fibroblast biology in the context of myocardial fibrosis, emphasizing their contributions to inflammation and extracellular matrix dysregulation and their interactions with cardiomyocytes and endothelial cells.

[Biomacromolecules] Scientists summarize progress in the design and application of ECM-mimetic peptides, focusing on their roles in tissue engineering, regenerative medicine, and drug delivery.

[Oorja Bio, Inc.] Oorja Bio, Inc. announced the presentation of the first-in-human Phase I clinical data for ORJ-001, a first-in-class therapeutic to treat IPF, demonstrating therapeutically relevant exposure and favorable tolerability in healthy volunteers.

[Cornell Chronicle] Five innovative immunology research projects have been selected for funding through the Cornell Center for Immunology's 2026 Multidisciplinary Seed Grants.

[University of Colorado Anschutz Cancer Center] Dr. Siddhartha Mitra recently received a three-year grant to develop chimeric antigen receptor (CAR) macrophages therapies to treat diffuse midline gliomas, a particularly deadly type of pediatric brain cancer.

[American Journal of Respiratory and Critical Care Medicine] Scientists characterized the differences in composition of the immune cells in the alveolar space of patients with chronic obstructive pulmonary disease versus healthy controls and the relation with severity of airflow limitation at a single cell resolution.